A practical reference on Ac-SDKP: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
is the radius of curvature of the menisci at the elongated ends of the droplet. This process is simple and consistently results in two droplets of equal volume. The conventional method of splitting an existing droplet by simply turning the splitting electrodes on and off produces new droplets of relatively equal volume. However, the new droplets formed by the conventional method show considerable difference in volume. This difference is caused by local perturbations due to the rapid mass transport. Even though the difference is negligible in some applications, it can still pose a problem in applications that are highly sensitive to variations in volume, such as immunoassays and DNA amplification. To overcome the limitation of the conventional method, an existing droplet can be split by gradually changing the potential of the electrodes at the splitting region instead of simply switching them on and off. Using this method, a noticeable improvement in droplet volume variation, from around 10% variation in volume to less than 1% variation in volume, has been reported.
=== History === During World War I, munitions workers in France fell ill and some died from DNP exposure. Stanford University academic Maurice L. Tainter learned of DNP's effect in raising the metabolic rate and causing weight loss and pioneered its use as a weight loss drug. Although he was aware of DNP's narrow therapeutic index, Tainter tried the drugs on obese patients and published successful results in 1933; average weight loss was 20 pounds (9.1 kg) and most recipients did not report adverse effects. In 1934, Tainter estimated that at least 100,000 people had been treated with DNP in the United States during its first year on the market and there had been three reported fatalities connected to the drug. Tainter argued that DNP was highly effective in raising the metabolic rate (up to 50 percent) and avoided the negative circulatory effects of desiccated thyroid, another weight loss drug in use at the time.
A fault on a power sub-transmission feeder causes a power shortage in the southern Far North District that affects 23,000 homes and businesses. 7 November – Local authorities in the Clutha District and Southland Region lift local states of emergency caused by the October 2025 New Zealand storms. 8 November – A wildfire breaks out in Tongariro National Park, engulfing 2,500 hectares and leading to the evacuation of campers and the closure of a nearby highway. 9 November: The wildfire in Tongariro National Park engulfs 2,500 hectares, leading to the evacuation of Whakapapa Village. Firefighters manage to contain 20% of the fire. Te Pāti Māori's national council votes overnight to expel MPs Mariameno Kapa-Kingi and Tākuta Ferris following several weeks of internal conflict. The decision is confirmed by the party's leadership the following day. The New Zealand government extends its suspension of NZ$29.8 million worth of funding to the Cook Islands over the next two financial years in response to the Cook Islands government signing several partnership agreements with China in February 2025. 10 November: The wildfire in the Tongariro National Park subsides due to rainfall and the efforts of firefighters to contain the blaze. Residents of Whakapapa Village are allowed to return. An estimated 3,000 hectares have been damaged by the wildfire. The contactless fare payment system Motu Move is launched on public buses and the ferry in Christchurch.
The first treatments with Adelaide-produced insulin were delivered by Robertson's Medical Science Club colleague, Dr. Trent Champion de Crespigny (Honorary Physician to the Adelaide Children's Hospital). The first treated was gravely-ill 9 years-old Dawson Hanna (1913–1926), at the Adelaide Children's Hospital on 7 January 1923, who lived for another three years. The first adult treated with Adelaide-produced insulin was the comatose and moribund 34 years-old Clifford Harry Cornish (1888–1954), at the Adelaide Hospital on 31 January 1923, who lived for another thirty years. All of the Adelaide-produced insulin used for these treatments had been delivered "free of charge" to the patients.
Sources: en.wikipedia.org
=== Compression gloves === Compression gloves are handwear designed to help prevent the occurrence of various medical disorders relating to blood circulation in the wrists and hands. They can be used to treat the symptoms of arthritis, though the medical benefits may be limited.
== Start-up == If the raw catalyst is supplied in the form of nickel oxide, it is necessary to reduce it to metallic nickel before it will operate properly. Alternative catalysts do not necessarily need a reduction treatment. Methanizers should not be heated without hydrogen being supplied to them.
=== Fruit and seed === The fruit develops from the ovary of the plant after fertilization, its flesh comprising the pericarp walls. The fruit contains locules, hollow spaces full of seeds. These vary among cultivated varieties. Some smaller varieties have two locules; globe-shaped varieties typically have three to five; beefsteak tomatoes have a great number of small locules; and plum tomatoes have very few, very small locules. The fruit contains lycopene that produces a red colour when ripe to attract animals that eat and disperse them elsewhere. However, not all tomatoes have same levels of lycopene; so not all of them have the same red colour when they ripe. Yellow tomatoes have levels of delta-carotene and lutein higher than lycopene, orange tomatoes have higher levels of beta-carotene and prolycopene. For propagation, the seeds need to come from a mature fruit, and must be lightly fermented to remove the gelatinous outer coating and then dried before use. The tomato has a mutualistic relationship with arbuscular mycorrhizal fungi such as Rhizophagus irregularis. Scientists use the tomato as a model species for investigating such symbioses.
A strain is a type of acute injury that occurs to the muscle or tendon. Similar to sprains, it can vary in severity, from a stretching of the muscle or tendon to a complete tear of the tendon from the muscle. Some of the most common places that strains occur are in the foot, back of the leg (hamstring), or back.
Governor Mike Parson appointed Schmitt as Missouri Attorney General to succeed Josh Hawley, who was elected to the U.S. Senate in 2018. Schmitt took office in January 2019. In 2020, he was elected to a full term. Schmitt resigned as attorney general in 2023 after his election to the U.S. Senate in 2022.
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.